Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy, safety, tolerability and dose-response relationship, using
oral corticosteroid (OCS) modulation, of 3 different doses of VR506 using a twice daily
regimen from a new dry powder inhaler (nDPI) for 16 weeks in subjects with severe persistent
asthma requiring OCS therapy, i.e. Step 5 treatment as defined by modified Global Initiative
for Asthma (GINA) guidelines 2011.